Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Auna $300 million high-yield notes offering
Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal…
Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645…
China Biologic going-private transaction
Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China…
Five Prime Therapeutics $173 million follow-on offering
Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an…
Bristol Myers Squibb $7 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its…
Affimed $75 million SEC-registered at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and…
Novo Nordisk acquisition of Emisphere Technologies
Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited…